| Lindsay M Griffin, MD | |
|
225 E Chicago Ave # 9, Chicago, IL 60611-2991 | |
| (608) 698-5551 | |
| Not Available |
| Full Name | Lindsay M Griffin |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 225 E Chicago Ave # 9, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023373198 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Connecticut Childrens Medical Center | Hartford, CT | Hospital |
| Hartford Hospital | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Connecticut Imaging Partners Llc | 4183649098 | 83 |
| Jefferson Radiology Pc | 8729982525 | 89 |
| Connecticut Imaging Partners Llc | 4183649098 | 83 |
| Jefferson Radiology Pc | 8729982525 | 89 |
News Archive
At a time when the nation's credit has been downgraded for the first time and our country is struggling to finance and reform existing entitlement programs, Obamacare's creation of new entitlements increases dependency on government and pushes our country deeper into a fiscal crisis of Greek proportion. As Congress and the president seek bipartisan ground to address the national debt, we must remember that the first step out of a hole is to stop digging.
In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
› Verified 1 days ago
| Entity Name | Jefferson Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396795951 PECOS PAC ID: 8729982525 Enrollment ID: O20031124000161 |
News Archive
At a time when the nation's credit has been downgraded for the first time and our country is struggling to finance and reform existing entitlement programs, Obamacare's creation of new entitlements increases dependency on government and pushes our country deeper into a fiscal crisis of Greek proportion. As Congress and the president seek bipartisan ground to address the national debt, we must remember that the first step out of a hole is to stop digging.
In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
› Verified 1 days ago
| Entity Name | Connecticut Imaging Partners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740315761 PECOS PAC ID: 4183649098 Enrollment ID: O20051011000041 |
News Archive
At a time when the nation's credit has been downgraded for the first time and our country is struggling to finance and reform existing entitlement programs, Obamacare's creation of new entitlements increases dependency on government and pushes our country deeper into a fiscal crisis of Greek proportion. As Congress and the president seek bipartisan ground to address the national debt, we must remember that the first step out of a hole is to stop digging.
In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
› Verified 1 days ago
| Entity Name | Tic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457702813 PECOS PAC ID: 4880972819 Enrollment ID: O20161026002352 |
News Archive
At a time when the nation's credit has been downgraded for the first time and our country is struggling to finance and reform existing entitlement programs, Obamacare's creation of new entitlements increases dependency on government and pushes our country deeper into a fiscal crisis of Greek proportion. As Congress and the president seek bipartisan ground to address the national debt, we must remember that the first step out of a hole is to stop digging.
In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
› Verified 1 days ago
| Entity Name | Farmington Imaging Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275987802 PECOS PAC ID: 7719265651 Enrollment ID: O20161028000552 |
News Archive
At a time when the nation's credit has been downgraded for the first time and our country is struggling to finance and reform existing entitlement programs, Obamacare's creation of new entitlements increases dependency on government and pushes our country deeper into a fiscal crisis of Greek proportion. As Congress and the president seek bipartisan ground to address the national debt, we must remember that the first step out of a hole is to stop digging.
In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsay M Griffin, MD 1130 N Dearborn St Apt 1710, Chicago, IL 60610-7118 Ph: (608) 698-5551 | Lindsay M Griffin, MD 225 E Chicago Ave # 9, Chicago, IL 60611-2991 Ph: (608) 698-5551 |
News Archive
At a time when the nation's credit has been downgraded for the first time and our country is struggling to finance and reform existing entitlement programs, Obamacare's creation of new entitlements increases dependency on government and pushes our country deeper into a fiscal crisis of Greek proportion. As Congress and the president seek bipartisan ground to address the national debt, we must remember that the first step out of a hole is to stop digging.
In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.
genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.
› Verified 1 days ago
Dr. Benjamin Jordan Meyer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7435 W Talcott Ave, Chicago, IL 60631 Phone: 773-774-8000 | |
Lauren Elizabeth Arsenault, MD Radiology Medicare: Medicare Enrolled Practice Location: 1653 W Congress Pkwy, Chicago, IL 60612 Phone: 312-942-5781 Fax: 312-942-7244 | |
Dr. Mohan Phatak, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 7435 W Talcott Ave, Chicago, IL 60631 Phone: 773-792-5138 Fax: 773-792-5124 | |
Janice Dieschbourg, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 155, Chicago, IL 60612 Phone: 312-563-3269 | |
Amir K Sepahdari, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5145 N California Avenue, Swedish Covenant Hospital, Chicago, IL 60625 Phone: 773-989-3814 Fax: 773-989-6230 | |
Dr. Amar Pravin Shah, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 461, Chicago, IL 60612 Phone: 312-942-5781 | |
Dr. Naveen Prabhakar, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 836 W Wellington Ave, Chicago, IL 60657 Phone: 773-296-7820 Fax: 773-296-7821 |